Revenue
0 USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
SPERO THERAPEUTICS, INC.
EDGARAnnual consolidated revenue for 2025: about USD 66.8M, using the latest reported figures. The previous period, 2024, was about USD 47.98M.
Latest quarter
- Cash and cash equivalents
- 50.8 million USD Source
Exact value
50774000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 58.1 million shares Source
Exact value
58146910 shares
Reported share-count change
3.49% · 1.96 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
47 million USD
2025-07-01 – 2026-06-30
Net income
7.38 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
19.6 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -4273000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -21695000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -12624000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -4273000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: 15864000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 10509000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: 15864000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-27.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 10 of 11 periods available· newest 2025-12-31
- Operating income: 11 of 11 periods available· newest 2025-12-31
- Net income: 10 of 11 periods available· newest 2025-12-31
- Operating cash flow: 11 of 11 periods available· newest 2025-12-31
- Capital expenditure: 6 of 11 periods available· newest 2020-12-31
- Total assets: 10 of 11 periods available· newest 2025-12-31
- Total liabilities: 10 of 11 periods available· newest 2025-12-31
- Current assets: 10 of 11 periods available· newest 2025-12-31
- Current liabilities: 10 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 10 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+39.2%Prior period
USD 47.98 million
–
Current period
USD 66.8 million
–
Exact inputs and evidence
66802000 − 47977000 = 18825000 USD
47977000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source66802000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 77.14 millionPrior period
−USD 68.57 million
–
Current period
USD 8.57 million
–
Exact inputs and evidence
8572000 − -68566000 = 77138000 USD
-68566000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source8572000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 10.82 millionPrior period
−USD 23.44 million
–
Current period
−USD 12.62 million
–
Exact inputs and evidence
-12624000 − -23444000 = 10820000 USD
-23444000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12624000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 66.8 million 100% of revenue
- Operating costs Derived USD 60.49 million 91% of revenue
- Operating income USD 6.31 million 9.5% of revenue
- Tax, interest and other Derived −USD 2.26 million −3.4% of revenue
- Net income USD 8.57 million 13% of revenue
Cash
- Operating cash flow −USD 12.62 million −19% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 Operating loss: operating costs were 10,017% of revenue.
- 2017 Operating loss: operating costs were 2,209% of revenue.
- 2018 Operating loss: operating costs were 1,179% of revenue.
- 2019 Operating loss: operating costs were 448% of revenue.
- 2020 Operating loss: operating costs were 948% of revenue.
- 2021 Operating loss: operating costs were 582% of revenue.
- 2022 Not shown: operating income or net income is not reported.
- 2023 Net income was higher than operating income, so the split is not drawn.
- 2024 Operating loss: operating costs were 253% of revenue.
- 2025 Net income was higher than operating income, so the split is not drawn.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 335000 | 33556000 Derived | -33221000 | -7730000 Derived | -25491000 | -29789000 Derived | Source
|
| 2017 2017-01-01 – 2017-12-31 | 1979000 | 43709000 Derived | -41730000 | -2987000 Derived | -38743000 | -39138000 Derived | Source
|
| 2018 2018-01-01 – 2018-12-31 | 3966000 | 46772000 Derived | -42806000 | -1106000 Derived | -41700000 | -42061000 Derived | Source
|
| 2019 2019-01-01 – 2019-12-31 | 18147000 | 81363000 Derived | -63216000 | -2316000 Derived | -60900000 | -50334000 Derived | Source
|
| 2020 2020-01-01 – 2020-12-31 | 9330000 | 88443000 Derived | -79113000 | -813000 Derived | -78300000 | -86029000 Derived | Source
|
| 2021 2021-01-01 – 2021-12-31 | 18256000 | 106227000 Derived | -87971000 | 1829000 Derived | -89800000 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 53509000 | 95706000 Derived | -42197000 | Unavailable | Unavailable | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 103781000 | 82300000 Derived | 21481000 | -1325000 Derived | 22806000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 47977000 | 121338000 Derived | -73361000 | -4795000 Derived | -68566000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 66802000 | 60488000 Derived | 6314000 | -2258000 Derived | 8572000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 66.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 335000 |
|
| 2017 | Revenue | 1979000 |
|
| 2018 | Revenue | 3966000 |
|
| 2019 | Revenue | 18147000 |
|
| 2020 | Revenue | 9330000 |
|
| 2021 | Revenue | 18256000 |
|
| 2022 | Revenue | 53509000 |
|
| 2023 | Revenue | 103781000 |
|
| 2024 | Revenue | 47977000 |
|
| 2025 | Revenue | 66802000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
39.2% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | No prior comparable period |
|
| 2017 | Year over year | 490.7% |
|
| 2018 | Year over year | 100.4% |
|
| 2019 | Year over year | 357.6% |
|
| 2020 | Year over year | -48.6% |
|
| 2021 | Year over year | 95.7% |
|
| 2022 | Year over year | 193.1% |
|
| 2023 | Year over year | 94% |
|
| 2024 | Year over year | -53.8% |
|
| 2025 | Year over year | 39.2% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 9.5% 2025
Net margin 12.8% 2025
Free cash flow margin -922.1% 2020
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Operating margin | -9,916.7% |
|
| 2017 | Operating margin | -2,108.6% |
|
| 2018 | Operating margin | -1,079.3% |
|
| 2019 | Operating margin | -348.4% |
|
| 2020 | Operating margin | -847.9% |
|
| 2021 | Operating margin | -481.9% |
|
| 2022 | Operating margin | -78.9% |
|
| 2023 | Operating margin | 20.7% |
|
| 2024 | Operating margin | -152.9% |
|
| 2025 | Operating margin | 9.5% |
|
| 2016 | Net margin | -7,609.3% |
|
| 2017 | Net margin | -1,957.7% |
|
| 2018 | Net margin | -1,051.4% |
|
| 2019 | Net margin | -335.6% |
|
| 2020 | Net margin | -839.2% |
|
| 2021 | Net margin | -491.9% |
|
| 2022-12-31 | Net margin | Not reported |
|
| 2023 | Net margin | 22% |
|
| 2024 | Net margin | -142.9% |
|
| 2025 | Net margin | 12.8% |
|
| 2016 | Free cash flow margin | -8,892.2% |
|
| 2017 | Free cash flow margin | -1,977.7% |
|
| 2018 | Free cash flow margin | -1,060.5% |
|
| 2019 | Free cash flow margin | -277.4% |
|
| 2020 | Free cash flow margin | -922.1% |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -12.6M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | -28959000 |
|
| 2017 | Operating cash flow | -39111000 |
|
| 2018 | Operating cash flow | -39625000 |
|
| 2019 | Operating cash flow | -50020000 |
|
| 2020 | Operating cash flow | -85872000 |
|
| 2021 | Operating cash flow | -64347000 |
|
| 2022 | Operating cash flow | -7731000 |
|
| 2023 | Operating cash flow | -32995000 |
|
| 2024 | Operating cash flow | -23444000 |
|
| 2025 | Operating cash flow | -12624000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -86M 2020
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | -29789000 |
|
| 2017 | Free cash flow | -39138000 |
|
| 2018 | Free cash flow | -42061000 |
|
| 2019 | Free cash flow | -50334000 |
|
| 2020 | Free cash flow | -86029000 |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
14.4% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Liabilities / assets | 53.8% |
|
| 2017 | Liabilities / assets | 9.1% |
|
| 2018 | Liabilities / assets | 10.2% |
|
| 2019 | Liabilities / assets | 29.7% |
|
| 2020 | Liabilities / assets | 14% |
|
| 2021 | Liabilities / assets | 48.4% |
|
| 2022 | Liabilities / assets | 39.2% |
|
| 2023 | Liabilities / assets | 41.4% |
|
| 2024 | Liabilities / assets | 58.3% |
|
| 2025 | Liabilities / assets | 14.4% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
7.59× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Current assets / current liabilities | 1.72× |
|
| 2017 | Current assets / current liabilities | 11.29× |
|
| 2018 | Current assets / current liabilities | 10.08× |
|
| 2019 | Current assets / current liabilities | 3.58× |
|
| 2020 | Current assets / current liabilities | 9.7× |
|
| 2021 | Current assets / current liabilities | 8.46× |
|
| 2022 | Current assets / current liabilities | 5.25× |
|
| 2023 | Current assets / current liabilities | 3.53× |
|
| 2024 | Current assets / current liabilities | 2.19× |
|
| 2025 | Current assets / current liabilities | 7.59× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 25.49 million Exact valueExact value: -25491000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 28.96 million Exact valueExact value: -28959000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 830,000 Exact valueExact value: 830000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.79 million Calculation and evidence-28959000 − 830000 USD Exact free cash flow: -29789000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2017-01-01 – 2017-12-31 | −USD 38.74 million Exact valueExact value: -38743000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 39.11 million Exact valueExact value: -39111000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 27,000 Exact valueExact value: 27000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 39.14 million Calculation and evidence-39111000 − 27000 USD Exact free cash flow: -39138000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2018-01-01 – 2018-12-31 | −USD 41.7 million Exact valueExact value: -41700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 39.63 million Exact valueExact value: -39625000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.44 million Exact valueExact value: 2436000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 42.06 million Calculation and evidence-39625000 − 2436000 USD Exact free cash flow: -42061000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2019 2019-01-01 – 2019-12-31 | −USD 60.9 million Exact valueExact value: -60900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 50.02 million Exact valueExact value: -50020000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 314,000 Exact valueExact value: 314000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 50.33 million Calculation and evidence-50020000 − 314000 USD Exact free cash flow: -50334000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | −USD 78.3 million Exact valueExact value: -78300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 85.87 million Exact valueExact value: -85872000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 157,000 Exact valueExact value: 157000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 86.03 million Calculation and evidence-85872000 − 157000 USD Exact free cash flow: -86029000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 89.8 million Exact valueExact value: -89800000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 64.35 million Exact valueExact value: -64347000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | Unavailable Not reported for this period. | −USD 7.73 million Exact valueExact value: -7731000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | USD 22.81 million Exact valueExact value: 22806000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 33 million Exact valueExact value: -32995000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 68.57 million Exact valueExact value: -68566000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 23.44 million Exact valueExact value: -23444000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | USD 8.57 million Exact valueExact value: 8572000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.62 million Exact valueExact value: -12624000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
46 filings · 2,383 latest values · 2,368 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001701108, 1701108, SPRO, edgar:1701108
Also known as SPERO THERAPEUTICS, INC., Spero Therapeutics, Inc., Spero Therapeutics, LLC